Genetically speaking, breast cancer is a heterogeneous disease.
Primary tumors are classified in types and subtypes according to the genes expressed or muted by their cells.
This background greatly conditions prognosis and subsequent progression of the disease.
'Triple negative' breast cancer (TNBC) constitutes a particularly challenging kind of carcinoma. It denotes three missing markers, which individually are associated with breast cancer.
While they are still vulnerable to conventional chemotherapy, they remain resistant to selective drugs designed to target the absent markers.
Thus, pharmacological resources to fight TNBCs are limited.
Additionally, those tumors are aggressive and have the ability to...